Payment overview · 2025
General Payments
$8,295.17
12 reported records · 4 companies
Healthcare provider profile · identity verified
Michael Dunleavy, DO
Allopathic & Osteopathic Physicians|Family Medicine · BARTLETT, IL · NPI 1811927239
Verified facts
What the public records show
CMS Open Payments records show Michael Dunleavy, DO received $8,295.17 in general payments during 2025 across 12 reported records.
BIOTRONIK INC. accounted for 74.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $6,187.54 | 74.6% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,000.00 | 24.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $93.47 | 1.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.16 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $5,936.11 | 5 |
| Grant | $2,000.00 | 1 |
| Food and Beverage | $359.06 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $38.80 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 695 | 188 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 484 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 421 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 83 |
| Metformin Hcl | Metformin Hcl | 293 | 85 |
| Gabapentin | Gabapentin | 291 | 64 |
| Lisinopril | Lisinopril | 281 | 75 |
| Losartan Potassium | Losartan Potassium | 279 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 67 |
| Alprazolam | Alprazolam | 246 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 66 |
| Furosemide | Furosemide | 216 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 44 |
| Omeprazole | Omeprazole | 169 | 46 |
| Tramadol Hcl | Tramadol Hcl | 167 | 34 |
| Sertraline Hcl | Sertraline Hcl | 145 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 42 |
| Glimepiride | Glimepiride | 140 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 138 | 99 |
| Baclofen | Baclofen | 133 | 67 |
| Methylprednisolone | Methylprednisolone | 129 | 94 |
| Montelukast Sodium | Montelukast Sodium | 128 | 36 |
| Allopurinol | Allopurinol | 127 | 34 |
| Metformin Hcl Er | Metformin Hcl | 123 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 23 |
| Eliquis | Apixaban | 114 | 23 |
| Trazodone Hcl | Trazodone Hcl | 114 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 61 |
| Potassium Chloride | Potassium Chloride | 110 | 23 |
| Simvastatin | Simvastatin | 105 | 30 |
| Azithromycin | Azithromycin | 104 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 40 |
| Famotidine | Famotidine | 89 | 31 |
| Carvedilol | Carvedilol | 87 | 23 |
| Lorazepam | Lorazepam | 82 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 21 |
| Meloxicam | Meloxicam | 72 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 52 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 66 | 17 |
| Finasteride | Finasteride | 61 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 16 |
| Celecoxib | Celecoxib | 60 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 17 |
| Fenofibrate | Fenofibrate | 56 | 14 |
| Atenolol | Atenolol | 55 | 15 |
| Prednisone | Prednisone | 55 | 20 |
| Benazepril Hcl | Benazepril Hcl | 53 | 12 |
| Clonazepam | Clonazepam | 52 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Ezetimibe | Ezetimibe | 51 | 18 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 34 |
| Cephalexin | Cephalexin | 44 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 40 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 15 |
| Diazepam | Diazepam | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 24 |
| Nystatin | Nystatin | 32 | 15 |
| Ozempic | Semaglutide | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 14 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Lactulose | Lactulose | 24 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 13 |
| Temazepam | Temazepam | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 11 |
| Methimazole | Methimazole | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,295.17 · 12 records | BIOTRONIK INC. | EMBLEM MRI S-ICD, LUX-Dx Insertable Cardiac Monitor, MERLIN@HOME, WATCHMAN Access System | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error